Prof. Joseph Press, the Medipress CEO, who previously headed the only Children Hospital in Israel, comments that “The P-Cure achievement shifts the use of Proton Therapy from marginal to mainstream clinical practice allowing virtually all radiotherapy departments to install the solu...
were already treated in the robotic setting. Following the success in SLNB, this hybrid concept is now increasingly adopted for research in receptor-targeted tracers (e.g., neuroendocrine tumors using Cy5-111In-DTPA-Tyr3-octreotate [156], prostate cancer using PSMA I&F [157] and breast canc...
(MEDI4736) and Tremelimumab Dual Immune Checkpoint Inhibition Phase I Multicenter Trial Combining Nivolumab, Alone or with Ipilimumab, Plus Hypofractionated Radiotherapy for Pretreated Advanced Stage Non-Small Cell Lung Cancer Patients Condition(s) A Phase I/II Study of Nivolumab Plus or Minus ...